sCD163 was positively associated with HDL cholesterol, T2D treatment, triglycerides, and the prescription of β-blockers, whereas CCB, CAD, and PAD were linked with a lowering in sCD163 (Supplementary Table S2). This evidence concerns the gene CD163 and peripheral arterial disease.